What type of study is this?

This is a Phase 1 study (also classified as: Randomized controlled trial).

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial assessed safety and pharmacokinetics of bexicaserin in healthy individuals, indicating good tolerability and rapid absorption.

Bexicaserin showed good safety and tolerability profiles in healthy participants after multiple doses.
The study revealed a pharmacokinetic pattern, with median Tmax around 1-2 hours and Cmax accumulation ranging from 1.5 to 5.1-fold.
Assessment included analyses of pharmacodynamics through prolactin changes, indicating engagement of 5-HT2C receptors.
Overall clearance of bexicaserin varied, supporting its progression into Phase 3 clinical trials.

Williams et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1 trial assessed safety and pharmacokinetics of bexicaserin in healthy individuals, indicating good tolerability and rapid absorption.